BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 30715679)

  • 1. CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges.
    Demirci S; Leonard A; Haro-Mora JJ; Uchida N; Tisdale JF
    Adv Exp Med Biol; 2019; 1144():37-52. PubMed ID: 30715679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
    Wen J; Tao W; Hao S; Zu Y
    J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9 system and its applications in human hematopoietic cells.
    Hu X
    Blood Cells Mol Dis; 2016 Nov; 62():6-12. PubMed ID: 27736664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 gene editing for curing sickle cell disease.
    Park SH; Bao G
    Transfus Apher Sci; 2021 Feb; 60(1):103060. PubMed ID: 33455878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
    Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
    Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9-based gene-editing technology for sickle cell disease.
    Ma L; Yang S; Peng Q; Zhang J; Zhang J
    Gene; 2023 Jul; 874():147480. PubMed ID: 37182559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
    Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.
    Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L
    Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system.
    Wattanapanitch M; Damkham N; Potirat P; Trakarnsanga K; Janan M; U-Pratya Y; Kheolamai P; Klincumhom N; Issaragrisil S
    Stem Cell Res Ther; 2018 Feb; 9(1):46. PubMed ID: 29482624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.
    Romero Z; Lomova A; Said S; Miggelbrink A; Kuo CY; Campo-Fernandez B; Hoban MD; Masiuk KE; Clark DN; Long J; Sanchez JM; Velez M; Miyahira E; Zhang R; Brown D; Wang X; Kurmangaliyev YZ; Hollis RP; Kohn DB
    Mol Ther; 2019 Aug; 27(8):1389-1406. PubMed ID: 31178391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus.
    Antoniani C; Meneghini V; Lattanzi A; Felix T; Romano O; Magrin E; Weber L; Pavani G; El Hoss S; Kurita R; Nakamura Y; Cradick TJ; Lundberg AS; Porteus M; Amendola M; El Nemer W; Cavazzana M; Mavilio F; Miccio A
    Blood; 2018 Apr; 131(17):1960-1973. PubMed ID: 29519807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
    Paschoudi K; Yannaki E; Psatha N
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revolutionising healing: Gene Editing's breakthrough against sickle cell disease.
    Dimitrievska M; Bansal D; Vitale M; Strouboulis J; Miccio A; Nicolaides KH; El Hoss S; Shangaris P; Jacków-Malinowska J
    Blood Rev; 2024 May; 65():101185. PubMed ID: 38493007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells.
    DeWitt MA; Magis W; Bray NL; Wang T; Berman JR; Urbinati F; Heo SJ; Mitros T; Muñoz DP; Boffelli D; Kohn DB; Walters MC; Carroll D; Martin DI; Corn JE
    Sci Transl Med; 2016 Oct; 8(360):360ra134. PubMed ID: 27733558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
    Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S
    N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-Cas9 Editing of the
    Sharma A; Boelens JJ; Cancio M; Hankins JS; Bhad P; Azizy M; Lewandowski A; Zhao X; Chitnis S; Peddinti R; Zheng Y; Kapoor N; Ciceri F; Maclachlan T; Yang Y; Liu Y; Yuan J; Naumann U; Yu VWC; Stevenson SC; De Vita S; LaBelle JL
    N Engl J Med; 2023 Aug; 389(9):820-832. PubMed ID: 37646679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
    Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
    Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease.
    Ramadier S; Chalumeau A; Felix T; Othman N; Aknoun S; Casini A; Maule G; Masson C; De Cian A; Frati G; Brusson M; Concordet JP; Cavazzana M; Cereseto A; El Nemer W; Amendola M; Wattellier B; Meneghini V; Miccio A
    Mol Ther; 2022 Jan; 30(1):145-163. PubMed ID: 34418541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system.
    Song B; Fan Y; He W; Zhu D; Niu X; Wang D; Ou Z; Luo M; Sun X
    Stem Cells Dev; 2015 May; 24(9):1053-65. PubMed ID: 25517294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation.
    Dever DP; Porteus MH
    Curr Opin Hematol; 2017 Nov; 24(6):481-488. PubMed ID: 28806273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.